In the present work we report on the click synthesis of a new camptothecin (CPT) prodrug based on anionic polyamidoamine (PAMAM) dendrimer intended for cancer therapy.
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INTRODUCTION
Dendrimers have attracted increasing attention as drug carriers in that they possess a high degree of molecular uniformity, high drug loading capacity, and the ability to accommodate various functional entities. [1] [2] [3] Thus, various dendrimer-based drug delivery platforms have been developed [4] [5] [6] [7] , and their utility for delivering anticancer drugs has been actively explored and yielded promising results. [8] [9] [10] [11] [12] [13] [14] Regardless, a commonly encountered problem is the heterogeneity of ligand and drug on the dendrimer surface during chemical synthesis. 15 It is essential to obtain a uniform distribution of ligand and drug for standardizing therapeutic effects and for the successful translation of dendrimer-based nanomedicines to clinical application. Robust and efficient coupling methods must be applied to overcome such issues.
Camptothecin is a plant alkaloid isolated from Camptotheca acuminata of the Nyssaceae family with remarkable anticancer activity by inhibiting both DNA and RNA synthesis. 16 Camptothecin has been used for the treatment of many different types of cancer despite its low water solubility and poor stability of the lactone form, a required form for therapeutic activity. 17 In particular, it is of advantage to use CPT to treat cancer as it selectively kills proliferating (Sphase) cells, thus exerting little to no toxicity to non-dividing normal cells resident of the brain. 18, 19 Polymer-CPT conjugates have been made by various methods. [20] [21] [22] Although several dendrimer-CPT derivatives have been made in the past, the efficiency using high capacity of dendrimer to deliver CPT was low. For instance, Thiagarajan et al. applied EDC/NHS chemistry to conjugate CPT to the dendrimer via a glycine spacer. 23 Less than 20% of CPT used in the reaction was successfully attached to the dendrimer. Copper-catalyzed azide-alkyne cycloaddition (CuAAC), the best known example of a "click" reaction, is a highly efficient and selective synthetic method. It has proven to be a powerful strategy for precisely loading drugs to 
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various polymeric carriers including dendrimers. 22, 24, 25 The current study reports on the use of click chemistry for the synthesis of water soluble polyamidoamine (PAMAM) dendrimercamptothecin (CPT) prodrug conjugates towards development of an enabling modular dendrimer-based delivery system for cancer therapy. In particular, we applied CuAAC for improving coupling reaction efficiency and to synthesize CPT-dendrimer conjugates. Anionic PAMAM dendrimer G4.5 was used as the carrier because of low toxicity and low non-specific cellular uptake. It was modified with polyethylene glycol (PEG) for improved water solubility and cytocompatibility. CPT was click coupled to the dendrimer carrier via a short heterobifunctional spacer. The click synthesis and characterization of the resulting dendrimerbased CPT prodrug and its therapeutic activity are reported herein.
EXPERIMENTAL SECTION
Materials. EDA core PAMAM dendrimer G4.5 caboxylate sodium salt was purchased The molar feed ratio of CPT to dendrimer in this reaction was 17:1, which was determined based on availability assessment for the alkyne groups on the dendrimer (see Supporting Information).
The obtained mixture underwent 3 times of freeze-pump-thaw cycling for degassing. Afterwards, CuBr (0.3 mg, 2.1 µmol) dissolved in 40 µL of DMSO was added to the mixture solution. The reaction mixture under nitrogen was stirred in dark overnight at room temperature and then poured into 5 mL of water. After 1 h-stirring, the solvents were removed under reduced pressure.
Extraction of unreacted CPT-APO was conducted by vortexing the obtained solid residue with ether (1 mL each time) followed by centrifugation for liquid-solid separation. The extraction procedure was repeated until CPT-APO became undetectable in ether by UV-Vis spectrophotometer. The remaining solid was dissolved in 1 mL of water followed by centrifugation. The liquid phase was collected and freeze-dried to yield CPT-G4. 
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RESULTS AND DISCUSSION
Characterization. We synthesized clickable PAMAM dendrimer G4.5 and used it as a carrier to deliver CPT as half generation PAMAM dendrimers are generally less toxic and have lower nonspecific cellular uptake as opposed to full generation dendrimers. 28, 29 Given the hydrophobicity of CPT, the dendrimer drug loading degree should be carefully controlled to avoid generating water insoluble entities. The incorporation of hydrophilic molecules such as PEG onto the dendrimer surface has proven effective in improving water solubility and enhancing cytocompatibility. 29, 30 Thus, this step was applied in the synthesis of our dendrimer- In vitro drug release studies were performed on CPT-G4.5-PEG conjugates to assess CPT release rate and potential utility of the resulting conjugates in delivery applications. RP-HPLC was used to measure CPT release kinetics from the conjugates. CPT was slowly released via hydrolysis of the ester bond between CPT and APO. About 10.6% CPT was released from the conjugates, following zero order kinetics over the course of 7 days ( Figure 5 ). CPT release kinetics may be modulated to achieve a desirable level and duration of drug action in future work. Efforts may include utility of more labile chemical bonds (e.g., pH sensitive bonds, enzymatic sensitive bonds) and more hydrophilic spacer for drug-spacer coupling for faster release, increasing drug loading, and so on. Drug Activity Evaluation. CPT interferes with the breakage-reunion reaction of DNA topoisomerase I (Top1) often referred to as the cleavable complex necessary to relieve DNA stress during DNA replication. 16 In doing so, a ternary complex between Top1-CPT-DNA is formed which is converted into single-strand breaks and subsequently into double-strand breaks during DNA replication. The cytotoxicity of the synthesized conjugates to human glioma U1242 cells was then assessed. CPT-G4.5-PEG cytotoxicity was found to be dose-dependent with an IC 50 of 5 µM ( Figure 5A ). In comparison, the IC 50 of free CPT was 27 nM. Conjugated CPT is expected to become therapeutically active following hydrolysis of the ester linkage between CPT and the dendrimer. As expected, the conjugated CPT exhibited much lower potency than free CPT at equivalent concentrations because of slow release as presented in Figure 5 . Thus, the conjugates are capable of sustaining therapeutic activity for a longer period of time. PEGylated PAMAM dendrimer carrier without CPT is cytocompatible and does not cause toxicity to cells at concentrations up to 50 µM ( Figure 5B ). Figure 7 . Cell cycle analysis. U1242 cells were left untreated (control), CPT at the concentration of 2×IC 50free , conjugated CPT at the concentration of 2×IC 50cojugated , and PPA-G4.5-PEG conjugates at the equivalent concentration of CPT-G4.5-PEG conjugates for various lengths of time (6, 12 , and 24 h). Overall, the current work illustrated the therapeutic activity of dendrimer-based CPT prodrug synthesized via click chemistry and it may exert long-lasting effect through slow release.
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The presence of a targeting moiety on the surface of a dendrimer molecule whose receptors are overexpressed on cancer cell membrane surface will enable the delivery of PAMAM dendrimerdrug conjugate to the tissue of the interest and improve specific uptake of the drug. The synthesized dendrimer-based CPT prodrug can be further functionalized for targeted therapy of many types of cancer such as glioblastoma multiforme (GBM). GBM is an aggressive form of brain cancer with poor prognosis and a median survival of only 12-15 months. In general, GBMs are resistant to standard treatment consisting of surgery followed by concurrent chemo-and radiotherapy. 32 New therapeutic approaches such as the use of small molecule radiosensitizers and gene therapy are under investigation for the treatment of GBM. 33, 34 However, treatment outcomes still depend largely on whether or not sufficient levels of therapeutic agent can be delivered to the brain tumor mass. 35 Considering that the blood-brain barrier (BBB), the blood cerebral spinal fluid, and the blood-tumor barrier hamper the administration of the therapeutic to the brain, efficient delivery still remains a challenge, and new technologies and delivery systems need to be developed. 36, 37 Despite that a number of carriers have been developed to facilitate drug entry into the brain, 32, 35, [37] [38] [39] dendrimers appear to be a suitable platform to deliver drugs along with BBB-specific ligands because of their multivalency. In future studies, coupling tumor-and BBB-specific ligands or other functional moieties to the synthesized dendrimer-CPT conjugates via click chemistry will be explored for directing and enhancing drug uptake by brain tumor cells.
CONCLUSIONS
CPT was coupled to PEGylated PAMAM dendrimer G4. 
